¹¹¹In-DOTA-biotin biodistribution in target and nontarget tissues. After ¹²⁵I-BC8-FP pretargeting (A), ¹²⁵I-CC49-FP pretargeting (B), and serial target site activity with BC8 PRIT (C). (A) Uptake of ¹²⁵I-BC8-FP and ¹¹¹In-DOTA-biotin in tissues (%ID/g) after pretargeted RIT. ¹²⁵I-BC8-FP (16.9 nmol/kg) was administered 24 hours before the ¹¹¹In-DOTA-biotin (1.2 mg/m²). Tissues were collected 72 hours after ¹²⁵I-BC8-FP and 48 hours after ¹¹¹In-DOTA-biotin. (B) Comparative uptake of control fusion protein (¹²⁵I-CC49-FP and ¹¹¹In-DOTA-biotin after pretargeted RIT). ¹²⁵I-CC49-FP (16.9 nmol/kg) was administered 24 hours before the ¹¹¹In-DOTA-biotin (1.2 mg/m²). Specimens shown were collected 72 hours after ¹²⁵I-CC49-FP and 48 hours after ¹¹¹In-DOTA-biotin. (C) Time-activity curves of ¹²⁵I-BC8-FP in the blood (●) and LNs (Δ) and ¹¹¹In-DOTA-biotin in the blood (□) and LNs (▽) of macaques treated with pretargeted RIT ¹²⁵I-BC8-FP (16.9 nmol/kg) administered 24 hours before the ¹¹¹In-DOTA-biotin (1.2 mg/m²). Serial blood and LN specimens were obtained at the time points indicated.